Mark S Riddle1, Patrick Connor2, Jamie Fraser3,4, Chad K Porter1, Brett Swierczewski5, Emma J Hutley6, Brook Danboise7, Mark P Simons8, Christine Hulseberg7, Tahaniyat Lalani3,4,9, Ramiro L Gutierrez1, David R Tribble3. 1. Naval Medical Research Center, Silver Spring, Maryland. 2. Academic Department of Military Medicine, Royal Centre for Defence Medicine, Birmingham, United Kingdom. 3. Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland. 4. Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland. 5. Armed Forces Research Institute for the Medical Sciences, Bangkok, Thailand. 6. Centre of Defence Pathology, Royal Centre for Defence Medicine, Birmingham, United Kingdom. 7. US Army Research Unit Kenya, Kericho. 8. Naval Medical Research Unit No. 6, Lima, Peru. 9. Naval Medical Center, Portsmouth, Virginia.
Abstract
BACKGROUND: Recommended treatment for travelers' diarrhea includes the combination of an antibiotic, usually a fluoroquinolone or azithromycin, and loperamide for rapid resolution of symptoms. However, adverse events, postdose nausea with high-dose azithromycin, effectiveness of single-dose rifaximin, and emerging resistance to front-line agents are evidence gaps underlying current recommendations. METHODS: A randomized, double-blind trial was conducted in 4 countries (Afghanistan, Djibouti, Kenya, and Honduras) between September 2012 and July 2015. US and UK service members with acute watery diarrhea were randomized and received single-dose azithromycin (500 mg; 106 persons), levofloxacin (500 mg; 111 persons), or rifaximin (1650 mg; 107 persons), in combination with loperamide (labeled dosing). The efficacy outcomes included clinical cure at 24 hours and time to last unformed stool. RESULTS: Clinical cure at 24 hours occurred in 81.4%, 78.3%, and 74.8% of the levofloxacin, azithromycin, and rifaximin arms, respectively. Compared with levofloxacin, azithromycin was not inferior (P = .01). Noninferiority could not be shown with rifaximin (P = .07). At 48 and 72 hours, efficacy among regimens was equivalent (approximately 91% at 48 and 96% at 72 hours). The median time to last unformed stool did not differ between treatment arms (azithromycin, 3.8 hours; levofloxacin, 6.4 hours; rifaximin, 5.6 hours). Treatment failures were uncommon (3.8%, 4.4%, and 1.9% in azithromycin, levofloxacin, and rifaximin arms, respectively) (P = .55). There were no differences between treatment arms with postdose nausea, vomiting, or other adverse events. CONCLUSIONS: Single-dose azithromycin, levofloxacin, and rifaximin with loperamide were comparable for treatment of acute watery diarrhea. CLINICAL TRIAL REGISTRATION: NCT01618591. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Recommended treatment for travelers' diarrhea includes the combination of an antibiotic, usually a fluoroquinolone or azithromycin, and loperamide for rapid resolution of symptoms. However, adverse events, postdose nausea with high-dose azithromycin, effectiveness of single-dose rifaximin, and emerging resistance to front-line agents are evidence gaps underlying current recommendations. METHODS: A randomized, double-blind trial was conducted in 4 countries (Afghanistan, Djibouti, Kenya, and Honduras) between September 2012 and July 2015. US and UK service members with acute watery diarrhea were randomized and received single-dose azithromycin (500 mg; 106 persons), levofloxacin (500 mg; 111 persons), or rifaximin (1650 mg; 107 persons), in combination with loperamide (labeled dosing). The efficacy outcomes included clinical cure at 24 hours and time to last unformed stool. RESULTS: Clinical cure at 24 hours occurred in 81.4%, 78.3%, and 74.8% of the levofloxacin, azithromycin, and rifaximin arms, respectively. Compared with levofloxacin, azithromycin was not inferior (P = .01). Noninferiority could not be shown with rifaximin (P = .07). At 48 and 72 hours, efficacy among regimens was equivalent (approximately 91% at 48 and 96% at 72 hours). The median time to last unformed stool did not differ between treatment arms (azithromycin, 3.8 hours; levofloxacin, 6.4 hours; rifaximin, 5.6 hours). Treatment failures were uncommon (3.8%, 4.4%, and 1.9% in azithromycin, levofloxacin, and rifaximin arms, respectively) (P = .55). There were no differences between treatment arms with postdose nausea, vomiting, or other adverse events. CONCLUSIONS: Single-dose azithromycin, levofloxacin, and rifaximin with loperamide were comparable for treatment of acute watery diarrhea. CLINICAL TRIAL REGISTRATION: NCT01618591. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Entities:
Keywords:
azithromycin; levofloxacin; randomized control trial; rifaximin; travelers’ diarrhea
Authors: Isabel Barreto Miranda; Ralf Ignatius; Roland Pfüller; Barbara Friedrich-Jänicke; Florian Steiner; Matthias Paland; Sebastian Dieckmann; Katharina Schaufler; Lothar H Wieler; Sebastian Guenther; Frank P Mockenhaupt Journal: J Travel Med Date: 2016-02-08 Impact factor: 8.490
Authors: David N Taylor; A Louis Bourgeois; Charles D Ericsson; Robert Steffen; Zhi-Dong Jiang; Jane Halpern; Robert Haake; Herbert L Dupont Journal: Am J Trop Med Hyg Date: 2006-06 Impact factor: 2.345
Authors: Charles D Ericsson; Herbert L DuPont; Pablo C Okhuysen; Zhi-Dong Jiang; Margaret W DuPont Journal: J Travel Med Date: 2007 Sep-Oct Impact factor: 8.490
Authors: J Philip Karl; Robyn A Barbato; Laurel A Doherty; Aarti Gautam; Sarah M Glaven; Robert J Kokoska; Dagmar Leary; Rebecca L Mickol; Matthew A Perisin; Andrew J Hoisington; Edward J Van Opstal; Vanessa Varaljay; Nancy Kelley-Loughnane; Camilla A Mauzy; Michael S Goodson; Jason W Soares Journal: Environ Microbiome Date: 2020-07-13
Authors: Tahaniyat Lalani; Jamie Fraser; Mark S Riddle; Ramiro L Gutierrez; Patrick W Hickey; David R Tribble Journal: Mil Med Date: 2019-11-01 Impact factor: 1.437
Authors: Nicole Maier; Mark S Riddle; Ramiro Gutiérrez; Jamie A Fraser; Patrick Connor; David R Tribble; Chad K Porter Journal: J Travel Med Date: 2022-01-17 Impact factor: 39.194
Authors: Mark S Riddle; Gregory J Martin; Clinton K Murray; Timothy H Burgess; Patrick Connor; James D Mancuso; Elizabeth R Schnaubelt; Timothy P Ballard; Jamie Fraser; David R Tribble Journal: Mil Med Date: 2017-09 Impact factor: 1.437
Authors: Ryan C Johnson; Joy D Van Nostrand; Michele Tisdale; Brett Swierczewski; Mark P Simons; Patrick Connor; Jamie Fraser; Angela R Melton-Celsa; David R Tribble; Mark S Riddle Journal: Open Forum Infect Dis Date: 2021-05-28 Impact factor: 3.835
Authors: J Philip Karl; Robyn A Barbato; Laurel A Doherty; Aarti Gautam; Sarah M Glaven; Robert J Kokoska; Dagmar Leary; Rebecca L Mickol; Matthew A Perisin; Andrew J Hoisington; Edward J Van Opstal; Vanessa Varaljay; Nancy Kelley-Loughnane; Camilla A Mauzy; Michael S Goodson; Jason W Soares Journal: Environ Microbiome Date: 2020-07-13
Authors: Tahaniyat Lalani; Michele D Tisdale; Jie Liu; Indrani Mitra; Cliff Philip; Elizabeth Odundo; Faviola Reyes; Mark P Simons; Jamie A Fraser; Emma Hutley; Patrick Connor; Brett E Swierczewski; Eric Houpt; David R Tribble; Mark S Riddle Journal: PLoS One Date: 2018-08-30 Impact factor: 3.240